why we have such need. I think Ms. Close did a great job of describing why it’s
important for us to consider, why it’s important to take care of diabetes early on. I am
still trying to figure out the relationship between actual macrovascular events and
diabetes control. I think there are a number of studies and we have been looking at that.
That’s still an issue. Just because diabetes is a risk factor for a later development of
these, it doesn’t mean that the administration of a drug in the context of coronary artery
diseases is safe.
higher events. I would love to - you should compare the event rate, which I don’t
remember off the top of my head, but I would be happy to compare the event rate from
CARDS to the event rate we are seeing here, which is 5 myocardial infractions out of a
4,000-patient trial where supposedly they are at high risk for myocardial infractions,
which is not the case. What was the first?
have a placebo group in these trials. You can look at the placebo event rate. The placebo
event rate is lower than most hypertension studies. I mean so, you know, it - yes, these
patients will have a lot of events if we follow them for 10 years. These are not the kind
of patients that will have a lot of events in six months or a year and all we have to do is
If you want to call this a high-risk population that’s fine; we, fortunately,
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
cardiovascular disease, so they haven’t declared themselves clinically, but the trial
itself certainly showed that they were at high risk for events.
DR. PARKS: Your comments or your thoughts on diabetes already being
DR. TEERLINK: That trial purposely tried to enroll patients who were at
observed or established as a cardiovascular or CHD risk equivalent.
DR. TEERLINK: It absolutely is. I think that’s why we are here. That’s